



VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

Date: 14th November, 2023

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai - 400001

Scrip code: 531015

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 14th November, 2023
Ref: Pursuant to Reg.30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,

With reference to the subject cited above, we wish to inform you that the Board of Directors of the Company at its meeting held on Tuesday, the 14th November, 2023 at 4.00 P.M at registered office of the Company, inter alia,

- (i) Approved the Un Audited Standalone Financial Results of the Company for the quarter ended 30th September, 2023 & Auditors Limited Review Report thereon;

The meeting commenced at 4.00 p.m. and concluded at 6~~30~~ p.m.

Request you to take the above information on records.

Thanking you,

Yours Faithfully,

For Venmax Drugs and Pharmaceuticals Limited

N. Krishnaiah

N. Krishnaiah
Director
DIN: 07279009





VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

VENMAX DRUGS AND PHARMACEUTICALS LIMITED Shed No.22, Plot No.84, Phase-1, IDA, Cherlapally, Hyderabad, Rangareddy, Telangana, Pincode-500035 (CIN: L20230TN188894C000102)						
Statement Of Un-audited Results For The Quarter and Six months ended 30th September 2023						
Particulars	Quarter ended 30th September, 2023	Quarter ended June 30,2023	Quarter ended 30th September, 2022	Six months ended 30th September, 2023	Six months ended 30th September, 2022	Year ended March 31,2023
	(In audited)	(In audited)	(In audited)	(In audited)	(In audited)	(Audited)
Income						
Revenue from operations	-	-	-	-	-	-
Total Revenue from operations	0	5.00	5.00	5.00	10.00	41.93
Other income	-	-	-	-	-	-
Total Income	-	5.00	5.00	5.00	10.00	41.93
Expenses						
Purchases	-	-	-	-	-	-
Changes in Inventory	-	-	-	-	-	-
Employee benefits expenses	0.60	0.00	0.99	1.20	1.29	3.02
Finance costs	-	-	-	-	-	-
Depreciation and amortisation expense	0.18	0.18	0.20	0.36	0.40	0.91
Other expenses	2.65	2.42	5.78	4.47	6.72	15.53
Total Expenses	3.43	2.60	6.97	6.03	8.41	19.86
Profit before tax	(2.83)	1.90	(1.94)	(1.03)	1.59	22.87
Tax expense						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	0.00	(0.00)	(0.00)	-	0.11	0.01
Net Profit for the Period	(2.83)	1.90	(1.94)	(1.03)	1.48	22.56
Other comprehensive income (OCI)						
(a) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Tax on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other Comprehensive Income	-	-	-	-	-	-
Total Comprehensive Income	(2.83)	1.90	(1.94)	(1.03)	1.48	22.56
Paid-up Equity Share Capital (Rs. 10/- per Equity Share)	523.89	523.89	523.89	523.89	523.89	523.89
Other Equity	-	-	-	-	-	999.04
Earnings per equity share (Face value of Rs.10/- each)						
(1) Basic	(0.05)	0.03	(0.03)	(0.03)	0.03	0.43
(2) Diluted	(0.05)	0.03	(0.03)	(0.03)	0.03	0.43

NOTES

a) The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendments) rules 2015.

b) The above financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 14th November, 2023.

c) The above statements have been prepared to the extent applicable, in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013 and other recognized Accounting Practices and Policies adopted by the Company w.e.1.01.04.2017. The financial results of the previous periods duly compiled with Ind AS have not been subjected to review or audit, however, the Management has exercised necessary diligence to ensure that the financial results provide a true and fair view of the Company's affairs.

d) The Statutory Auditors of the Company have carried out "limited review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.

e) The Company is engaged in activities of trading of bulk drugs, intermediates and biotech products. Hence Segment reporting is not applicable.

For and on Behalf of Board of Directors

H. Krishanish
H. Krishanish
Director
DIN- 07279609

Date : 14-11-2023
Place : Hyderabad.



M/s. VENMAX DRUGS AND PHARMACEUTICALS LIMITED
 Shed No.22, Plot No.84, Phase-1, IDA, Cherlapally, Hyderabad, Rangareddy, Telangana, Pincode-500055
 (CIN: L24230TG1988PLC009102)

Standalone Balance Sheet as at 30th September, 2023

(Rs. In lakhs unless otherwise stated)

Particulars	As at 30th September, 2023 Unaudited	As at 31 March, 2023 Audited
ASSETS		
(1) Non Current Assets		
(a) Property, Plant and Equipment	4.74	5.00
(b) Capital Work-In-Progress		
(c) Intangible Assets	2.19	2.30
(d) Financial Assets		
(i) Non-Current Investments		
(ii) Trade and Other Receivables		
(iii) Long Term Loans and Advances		
(d) Deferred Tax Assets (Net)		
(e) Other Non-Current Assets		
Non-Current Assets	6.93	7.30
(2) Current Assets		
(a) Inventories		
(b) Financial Assets		
(i) Investments		
(ii) Trade and Other Receivables	8.64	3.64
(iii) Cash and Cash Equivalents	0.03	0.03
(iv) Short Term Loans and Advances		
(c) Other Current Assets	10.17	10.17
Current Assets	18.84	13.84
Total Assets	25.77	21.14
LIABILITIES AND EQUITY		
(1) Equity		
(a) Share Capital	523.89	523.89
(b) Other Equity	(596.37)	(595.34)
(c) Share warrants application money pending allotment		
Equity	(72.48)	(71.45)
(2) Non Current Liabilities		
(a) Financial Liabilities		
(i) Long Term Borrowings		
(b) Provisions		
(c) Deferred Tax Liabilities (Net)	0.46	0.47
(d) Other Non-current Liabilities		
Non-Current Liabilities	0.46	0.47
(3) Current Liabilities		
(a) Financial Liabilities		
Borrowings	35.21	35.21
Other Financial Liabilities	15.31	15.31
(i) Trade Payables		
Micro and small enterprises		
Other than micro and small enterprises	32.85	32.85
(b) Short Term Provisions	1.18	1.18
(c) Other Current Liabilities	13.23	7.57
Current Liabilities	97.78	92.12
Total Liabilities	25.77	21.14
	-0.00	-0

For and on Behalf of Board of Director

N Krishnaiah
N Krishnaiah

Director

DIN:- 07279009

Date : 14-11-2023
 Place : Hyderabad.



M/s. VENMAX DRUGS AND PHARMACEUTICALS LIMITED
 Shed No.22, Plot No.84, Phase-1, IDA, Cherlapally, Hyderabad, Rangareddy, Telangana, Pincode-
 500055

(CIN: L24230TG1988PLC009102)

Cash Flow Statement for the six months ended 30th September 2023

PARTICULARS	As at 30/09/2023	Year ended Mar 31, 2023
	UnAudited	Audited
A) CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit as per Profit & Loss A/c	-1.03	22.57
Adjustment for :		
Depreciation	0.37	0.80
Other comprehensive income		-
Net Operating Profit Before Working Capital	-0.66	23.38
Changes		
Adjustment for :		
Trade & Other Receivables	-5.00	-
Changes in inventory	-	-
Other Current Assets	-	(0.59)
Trade Payables	-	(14.21)
Other Financial liabilities	-	(8.89)
Other current liabilities	5.66	-
Provisions	-	-
Net Cash from Operating Activities	0.00	(0.31)
Direct taxes paid		-
Net Cash from Operating Activities	0.00	(0.31)
B) CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	-	-
Net Cash from Investing Activities	-	-
C) CASH FLOW FROM FINANCING ACTIVITIES		
From Bank Borrowings		
Proceeds from long/short term borrowings	-	0.31
Net Cash from Financing Activities	-	0.31
Net Increase in Cash & Cash Equivalents	0.00	-
Add : Opening Cash & Cash Equivalents	0.03	0.03
Cash and Cash equivalents at the end of the year	0.03	0.03
1) Cash and Cash equivalents includes:		
Particulars		Year ended Mar 31, 2023
Cash on hand	0.02	0.02
Cash Equivalents:		
Current Accounts	0.01	0.01
Total	0.03	0.03



Independent Auditor's Limited Review Report on the Quarterly Unaudited Financial Results of The Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Venmax Drugs and Pharmaceuticals Limited

We have reviewed the accompanying Statement of unaudited financial results of Venmax Drugs and Pharmaceuticals Limited (the "Company") for the quarter and six months ended September 30, 2023 (the "Statement") attached herewith, being submitted by the Company, pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the Listing Regulations").

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG And CO
Chartered Accountants
FRN: 00096555

Giridhari

GIRIDHARI LAL TOSHNIWAL
(Partner)
M.No-205140



Udin No: 23205140B6UN0EHM10

Place: Hyderabad
Date: 14/11/2023